Autoimmune Hepatitis

PHILADELPHIA — Mycophenolate mofetil appeared to be more efficacious and tolerable than azathioprine in patients with autoimmune hepatitis, especially among those aged older than 50 years and with lower IgG levels, according to a presenter.

PHILADELPHIA — In this video, Nancy S. Reau, MD, FAASLD, AGAF, speaks with Healio about findings from a systemic review and meta-analysis on the efficacy of mycophenolate mofetil compared with azathioprine for autoimmune hepatitis.

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine at Stanford University, discusses a plenary session about the “emerging role” of mycophenolate mofetil for the treatment of autoimmune hepatitis.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

Mycophenolate mofetil was superior to azathioprine in achieving biochemical remission in treatment-naive patients with autoimmune hepatitis who were also treated with prednisolone, according to data presented at EASL Congress.

An MRI-derived, noninvasive tissue biomarker improved autoimmune hepatitis management by distinguishing patients in biochemical remission as well as those at risk for relapse, according to a study published in eClinicalMedicine.

Maternal autoimmune hepatitis correlated with five-fold higher odds of preterm birth; however, cirrhosis did not impact these odds, according to study results.

Recurrent autoimmune hepatitis after liver transplantation affected graft and overall survival, according to a presentation at the International Liver Congress.

Aggressive steroid regimens – with doses as high as 60 mg per day – have become the “new mantra” for treating patients with autoimmune hepatitis, according to a presenter at the 2020 Rheumatology Nurses Society Annual Conference.

Patients with autoimmune hepatitis who had a rapid response after treatment were the most likely to achieve normalization of transaminase levels in the following year and had a lower risk for liver-related death or transplantation, according to results of a retrospective study.